Piekarczyk Piotr, Lechowicz Urszula, Szopiński Janusz, Polaczek Mateusz, Błasińska Katarzyna, Modrzewska Katarzyna
3rd Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Department of Genetics and Clinical Immunology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Diagnostics (Basel). 2025 Mar 25;15(7):842. doi: 10.3390/diagnostics15070842.
Molecular testing plays a crucial role in lung cancer diagnosis and management. While single-gene tests (SGTs) remain an important diagnostic tool, developments in novel methods such as next generation sequencing (NGS) provide a more precise mutational profile and enable the targeted treatment of a larger scope of mutation-driven cancers. We present a case of a patient with a rare variant lung adenocarcinoma, who was misdiagnosed using a SGT. The initial treatment with immunotherapy was unsuccessful. The patient could have benefited if NGS had been performed instead of traditional real-time polymerase chain reaction (RT-PCR) and if adequate tyrosine kinase inhibitor treatment was initiated at the time of diagnosis.
分子检测在肺癌的诊断和管理中起着至关重要的作用。虽然单基因检测(SGTs)仍然是一种重要的诊断工具,但新一代测序(NGS)等新方法的发展提供了更精确的突变图谱,并能够对更大范围的由突变驱动的癌症进行靶向治疗。我们报告了一例罕见的变异型肺腺癌患者,该患者使用单基因检测被误诊。最初的免疫治疗未成功。如果当时进行的是NGS而非传统的实时聚合酶链反应(RT-PCR),并且在诊断时就开始进行充分的酪氨酸激酶抑制剂治疗,该患者可能会受益。